Technology Networks interviewed Dr. Pooja Swali, the first author of a new study that conducted a pangenome analysis to trace ...

Shares of Merus NV (NASDAQ:MRUS) were trading at $54.35, up $12.75, or 30%, on interim data as of Feb. 27 from the phase II trial of bispecific antibody petosemtamab in combination with Merck & Co.

IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that it has filed a request for withdrawal with the Securities and ...

(NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that it has entered into definitive agreements for the issuance and sale of an ...

IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that it has filed ...

Charles River Laboratories International, Inc. CRL expands its products and services across the drug discovery and early-stage development continuum through targeted partnerships and acquisitions. The ...

Thermo Fisher Scientific has introduced the Applied Biosystems™ MagMAX™ Pro HT NoSpin Plasmid MiniPrep Kit to meet the ...

Most relapsing fever bacteria that infect humans are spread by ticks, but Borrelia recurrentis is unique in being transmitted between humans via body ...

Researchers demonstrated that specific electromagnetic wave frequencies can disrupt the SARS-CoV-2 Spike protein structure in ...

Somatic hypermutation (SHM) of immunoglobulin variable (V) regions modulates antibody-antigen affinity is initiated by activation-induced cytidine deaminase (AID) on single-stranded DNA (ssDNA).

This study identifies 53BP1 as an interaction partner of GMCL1 (a likely CUL3 substrate receptor). The study seeks to link this finding to regulation of the mitotic surveillance pathway and paclitaxel ...